Sentinel lymph node biopsy for cutaneous melanoma: results of 10 years' experience in two regional training hospitals in the Netherlands. (Q53647601)

16 May 2018

title

Sentinel lymph node biopsy for cutaneous melanoma: results of 10 years' experience in two regional training hospitals in the Netherlands. (English)

1 reference

16 May 2018

0 references

0 references

0 references

Frank J van den Broek

1

1 reference

16 May 2018

Pim C Sloots

2

1 reference

16 May 2018

Jan-Willem D de Waard

3

1 reference

16 May 2018

Rudi M Roumen

4

1 reference

16 May 2018

publication date

9 March 2012

1 reference

16 May 2018

International Journal of Clinical Oncology

published in

1 reference

16 May 2018

volume

18

1 reference

16 May 2018

issue

3

1 reference

16 May 2018

page(s)

428-434

1 reference

16 May 2018

https://scigraph.springernature.com/pub.10.1007/s10147-012-0399-3

exact match

0 references

cites work

Natural history of invasive cutaneous melanoma in Styria, Austria 2001-2003.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

New TNM melanoma staging system: linking biology and natural history to clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Sentinel-node biopsy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Sentinel-node biopsy or nodal observation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

National trials involving lymphatic mapping for melanoma: the Multicenter Selective Lymphadenectomy Trial, the Sunbelt Melanoma Trial, and the Florida Melanoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0399-3

Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status

21 January 2018

1 reference

12 December 2020

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger

1 reference

12 December 2020

Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes.

1 reference

12 December 2020

Technical details of intraoperative lymphatic mapping for early stage melanoma

1 reference

12 December 2020

Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma

1 reference

12 December 2020

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial

1 reference

12 December 2020

Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity

1 reference

12 December 2020

Is sentinel lymph node biopsy of therapeutic relevance for melanoma?

1 reference

12 December 2020

Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.

1 reference

12 December 2020

High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma

1 reference

12 December 2020

A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma

1 reference

12 December 2020

10.1007/S10147-012-0399-3

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018